Baird noted Soleno Therapeutics (SLNO) shares have traded, directionally, with Applied Therapeutics shares over the last couple of trading days, as they are both FDA regulatory plays on non-standard applications. However, since they are not directly comparable, Baird says they would use the weakness in Soleno Therapeutics as a buying opportunity and they maintain their Outperform rating and $72 price target on the shares.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLNO:
- Short Report: Bears look to fade Archer Aviation ascent
- Soleno Therapeutics announces U.S.. FDA to ended review period for NDA
- Soleno Therapeutics Reports Q3 Progress and Financials
- Soleno Therapeutics reports Q3 EPS($1.83) , consensus (63c)
- Is SLNO a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
